The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Final results of 4-monthly screening in the UK Familial Ovarian Cancer Screening Study (UKFOCSS Phase 2).
Adam N Rosenthal
Honoraria - Fujirebio Diagnostics
Research Funding - Cancer Research UK; The BUPA Foundatiom; The Eve Appeal; UK Department of Health
Lindsay Fraser
No relevant relationships to disclose
Susan Philpott
No relevant relationships to disclose
Ranjit Manchanda
Honoraria - Abbott Laboratories
Philip Badman
No relevant relationships to disclose
Richard Hadwin
No relevant relationships to disclose
D. Gareth Evans
Expert Testimony - Marie DuPlessis
Diana Eccles
No relevant relationships to disclose
Steven James Skates
Research Funding - Fujirebio Diagnostics
James Mackay
No relevant relationships to disclose
Usha Menon
Stock Ownership - Abcodia
Research Funding - Cancer Research UK; Medical Research Council; National Institute for Health Research; National Institutes for Health
Ian Jacobs
Consultant or Advisory Role - Abcodia; Becton-Dickinson; Women's Health Specialists
Stock Ownership - Abcodia
Research Funding - Becton-Dickinson; Cancer Research UK; Medical Research Council